{"id":9498,"date":"2026-11-16T08:04:00","date_gmt":"2026-11-16T07:04:00","guid":{"rendered":"https:\/\/www.pjpharma.it\/?p=9498"},"modified":"2026-11-11T12:24:41","modified_gmt":"2026-11-11T11:24:41","slug":"ft-ce-12-clinical-study-on-nasal-congestion","status":"publish","type":"post","link":"https:\/\/www.pjpharma.it\/en\/ft-ce-12-clinical-study-on-nasal-congestion\/","title":{"rendered":"FT.CE.12: Clinical Study on Nasal Congestion"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\">FT.CE.12: Clinical Results for Nasal Symptoms in Children<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>FT.CE.12<\/strong> is a medical device based on a pH-controlled isotonic saline solution formulated with <strong>N-acetylcysteine (NAC) and methylsulfonylmethane (MSM)<\/strong>. It was developed to support nasal hygiene, hydrate the nasal mucosa, and help manage secretions associated with nasal congestion.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In March 2026, <strong>Gruppo Farmaimpresa conducted a paediatric clinical study on FT.CE.12<\/strong> involving <strong>20 children aged 3 to 12 years<\/strong>. The study aimed to assess the device\u2019s efficacy and safety in managing nasal and nasopharyngeal symptoms using the SNOT-22 questionnaire (<em>Sino-Nasal Outcome Test-22<\/em>).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">After 16\u201317 days of treatment, the total SNOT-22 score decreased significantly from <strong>8.16 to 3.37 points (p &lt; 0.001).<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The study also found significant improvements in <strong>nasal congestion, cough, and postnasal drip<\/strong>, providing preliminary clinical data supporting the use of FT.CE.12 for upper respiratory tract health.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Nasal Congestion in Children: Symptoms and Associated Problems<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Nasal congestion in children<\/strong> is common and is often associated with colds, upper respiratory tract infections, and inflammation of the nasal mucosa.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A build-up of secretions and blockage of the nasal passages can make breathing difficult and cause discomfort that interferes with daily activities.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Common symptoms include the following.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Nasal obstruction<\/strong>, with difficulty breathing through the nose.<\/li>\n\n\n\n<li><strong>Rhinorrhoea<\/strong>, characterised by excessive nasal discharge.<\/li>\n\n\n\n<li><strong>Thick mucus<\/strong> that is difficult to clear naturally.<\/li>\n\n\n\n<li><strong>Cough<\/strong>, sometimes associated with postnasal drip.<\/li>\n\n\n\n<li><strong>Irritation and dryness of the nasal mucosa<\/strong>.<\/li>\n\n\n\n<li><strong>Sleep disturbances<\/strong> related to breathing discomfort.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">In these situations, nasal hygiene solutions can help mechanically remove secretions and keep the nasal mucosa hydrated.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">FT.CE.12 was developed by combining an isotonic saline solution with functional ingredients to support upper respiratory tract health.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">FT.CE.12: NAC and MSM Formulation for Nasal Hygiene<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">FT.CE.12 is a <strong>medical device based on a pH-controlled isotonic saline solution<\/strong> containing N-acetylcysteine (NAC) and methylsulfonylmethane (MSM).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The formulation is designed to help cleanse the nasal passages and manage secretions associated with congestion and rhinorrhoea.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The main ingredients serve complementary functions.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>N-acetylcysteine (NAC)<\/strong> has mucolytic properties and is used to help thin secretions.<\/li>\n\n\n\n<li><strong>Methylsulfonylmethane (MSM)<\/strong> is included in the formulation to support nasal mucosal health.<\/li>\n\n\n\n<li><strong>Sodium chloride in isotonic solution<\/strong> helps hydrate and mechanically cleanse the nasal passages.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">FT.CE.12 Clinical Study: Methodology and Paediatric Population<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The FT.CE.12 clinical study assessed changes in nasal and nasopharyngeal symptoms in children who received the treatment.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The study used a <strong>single-arm, uncontrolled, pre\u2013post design<\/strong>, comparing patients\u2019 symptoms before and after treatment.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The study enrolled <strong>20 children<\/strong> aged 3 to 12 years, with a median age of 5 years.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Assessments were carried out at two time points.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>T0 (baseline)<\/strong> before treatment began.<\/li>\n\n\n\n<li><strong>T1 (follow-up)<\/strong> after 16\u201317 days of treatment.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Efficacy was assessed using the <strong>SNOT-22 (Sino-Nasal Outcome Test-22)<\/strong>, a 22-item clinical questionnaire that measures the severity of sinonasal symptoms and their impact on quality of life. Each item is scored from 0 to 5. <strong>Higher scores indicate more severe symptoms<\/strong>, and a decrease in score indicates improvement.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Study Results: Significant Reduction in SNOT-22 Score<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The study\u2019s primary endpoint was the change in total SNOT-22 score between T0 and T1.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The study reported the following results.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mean SNOT-22 score at T0<\/strong> \u2014 8.16 \u00b1 3.13 points.<\/li>\n\n\n\n<li><strong>Mean SNOT-22 score at T1<\/strong> \u2014 3.37 \u00b1 3.18 points.<\/li>\n\n\n\n<li><strong>Mean reduction<\/strong> \u2014 4.79 \u00b1 2.90 points.<\/li>\n\n\n\n<li><strong>Statistical significance<\/strong> \u2014 p &lt; 0.001.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The reduction was approximately <strong>58.7% of the mean baseline score<\/strong>, indicating an overall improvement in the symptoms assessed by the questionnaire.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The analysis of individual scores also found that <strong>95% of patients<\/strong> had a lower SNOT-22 score at follow-up, and <strong>74%<\/strong> had a reduction of more than 50% from baseline.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">These findings suggest an association between treatment with FT.CE.12 and improvement in nasal and nasopharyngeal symptoms in the children studied.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>FT.CE.12 Clinical Chart: SNOT-22 Scores at T0 and T1<\/strong><\/h3>\n\n\n\n<figure class=\"wp-block-image size-full\"><a href=\"https:\/\/www.pjpharma.it\/wp-content\/uploads\/2026\/11\/grafico-clinico-ft.ce_.12.png\"><img fetchpriority=\"high\" decoding=\"async\" width=\"915\" height=\"780\" src=\"https:\/\/www.pjpharma.it\/wp-content\/uploads\/2026\/11\/grafico-clinico-ft.ce_.12.png\" alt=\"\" class=\"wp-image-9493\" srcset=\"https:\/\/www.pjpharma.it\/wp-content\/uploads\/2026\/11\/grafico-clinico-ft.ce_.12.png 915w, https:\/\/www.pjpharma.it\/wp-content\/uploads\/2026\/11\/grafico-clinico-ft.ce_.12-300x256.png 300w, https:\/\/www.pjpharma.it\/wp-content\/uploads\/2026\/11\/grafico-clinico-ft.ce_.12-599x511.png 599w, https:\/\/www.pjpharma.it\/wp-content\/uploads\/2026\/11\/grafico-clinico-ft.ce_.12-767x654.png 767w\" sizes=\"(max-width: 915px) 100vw, 915px\" \/><\/a><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The chart shows a <strong>clear decrease in the SNOT-22 score<\/strong> between baseline and follow-up.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The mean score fell from 8.16 points at T0 to 3.37 points at T1, a mean difference of 4.79 points.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The bars represent mean scores at the two assessment points, and the vertical lines show the variability of the results.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The <strong>p-value of less than 0.001<\/strong> indicates that the observed difference was statistically significant.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The decrease in score suggests an overall improvement in patient-reported symptoms. Without a control group, the study could not determine how much of the observed improvement was attributable to the device.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Nasal Congestion, Cough, and Postnasal Drip: Clinical Results<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">In addition to the decrease in the total SNOT-22 score, the <strong>FT.CE.12<\/strong> clinical study found statistically significant improvements in three main symptoms: <strong>nasal congestion, cough, and postnasal drip<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">After 16\u201317 days of treatment, the <strong>relative reduction in symptom frequency<\/strong> was 60% for nasal congestion, 62.5% for cough, and 46.2% for postnasal drip.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><a href=\"https:\/\/www.pjpharma.it\/wp-content\/uploads\/2026\/11\/risultati-clinici-cngestione-nasale-tosse-e-secrezioni.png\"><img decoding=\"async\" width=\"897\" height=\"247\" src=\"https:\/\/www.pjpharma.it\/wp-content\/uploads\/2026\/11\/risultati-clinici-cngestione-nasale-tosse-e-secrezioni.png\" alt=\"\" class=\"wp-image-9494\" srcset=\"https:\/\/www.pjpharma.it\/wp-content\/uploads\/2026\/11\/risultati-clinici-cngestione-nasale-tosse-e-secrezioni.png 897w, https:\/\/www.pjpharma.it\/wp-content\/uploads\/2026\/11\/risultati-clinici-cngestione-nasale-tosse-e-secrezioni-766x211.png 766w, https:\/\/www.pjpharma.it\/wp-content\/uploads\/2026\/11\/risultati-clinici-cngestione-nasale-tosse-e-secrezioni-300x83.png 300w, https:\/\/www.pjpharma.it\/wp-content\/uploads\/2026\/11\/risultati-clinici-cngestione-nasale-tosse-e-secrezioni-599x165.png 599w\" sizes=\"(max-width: 897px) 100vw, 897px\" \/><\/a><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The findings suggest an improvement in nasal and nasopharyngeal symptoms in the children studied, providing preliminary clinical data supporting the use of FT.CE.12 for nasal hygiene and upper respiratory tract health.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">FT.CE.12: Ready-to-Market and Private Label Medical Device<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Are you looking for a <strong>paediatric nasal hygiene medical device<\/strong> that is ready to market or can be customised for <strong>private label<\/strong>?<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>FT.CE.12<\/strong> is an isotonic nasal solution containing N-acetylcysteine (NAC) and methylsulfonylmethane (MSM). It offers pharmaceutical companies and distributors an opportunity to expand their respiratory product portfolios.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Gruppo Farmaimpresa<\/strong> offers FT.CE.12 as a <strong>ready-to-market or private label solution<\/strong>, with supporting clinical data and customisation options for your market.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">To explore partnership opportunities, see Farmaimpresa\u2019s services for <a href=\"https:\/\/farmaimpresa.com\/it\/dispositivi-medici\/\" rel=\"noopener\" target=\"_blank\">medical device manufacturing<\/a> and <a href=\"https:\/\/farmaimpresa.com\/it\/servizi\/\" rel=\"noopener\" target=\"_blank\">product development and clinical studies<\/a>.<\/p>\n\n\n<style>.wp-block-kadence-advancedbtn.kb-btns9498_e32968-d2{gap:var(--global-kb-gap-xs, 0.5rem );justify-content:center;align-items:center;}.kt-btns9498_e32968-d2 .kt-button{font-weight:normal;font-style:normal;}.kt-btns9498_e32968-d2 .kt-btn-wrap-0{margin-right:5px;}.wp-block-kadence-advancedbtn.kt-btns9498_e32968-d2 .kt-btn-wrap-0 .kt-button{color:#555555;border-color:#555555;}.wp-block-kadence-advancedbtn.kt-btns9498_e32968-d2 .kt-btn-wrap-0 .kt-button:hover, .wp-block-kadence-advancedbtn.kt-btns9498_e32968-d2 .kt-btn-wrap-0 .kt-button:focus{color:#ffffff;border-color:#444444;}.wp-block-kadence-advancedbtn.kt-btns9498_e32968-d2 .kt-btn-wrap-0 .kt-button::before{display:none;}.wp-block-kadence-advancedbtn.kt-btns9498_e32968-d2 .kt-btn-wrap-0 .kt-button:hover, .wp-block-kadence-advancedbtn.kt-btns9498_e32968-d2 .kt-btn-wrap-0 .kt-button:focus{background:#444444;}<\/style>\n<div class=\"wp-block-kadence-advancedbtn kb-buttons-wrap kb-btns9498_e32968-d2\"><style>ul.menu .wp-block-kadence-advancedbtn .kb-btn9498_8581bf-8c.kb-button{width:initial;}.wp-block-kadence-advancedbtn .kb-btn9498_8581bf-8c.kb-button{padding:var(--kb-btn-padding);margin:var(--kb-btn-margin);box-shadow:none;}.wp-block-kadence-advancedbtn .kb-btn9498_8581bf-8c.kb-button:hover, .wp-block-kadence-advancedbtn .kb-btn9498_8581bf-8c.kb-button:focus{box-shadow:var(--kb-btn-shadow-hover, none);}<\/style><span class=\"kb-button kt-button button kb-btn9498_8581bf-8c kt-btn-size-standard kt-btn-width-type-auto kb-btn-global-fill kt-btn-has-text-true kt-btn-has-svg-false wp-block-kadence-singlebtn\"><span class=\"kt-btn-inner-text\">Contact us<\/span><\/span><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>FT.CE.12: Clinical Results for Nasal Symptoms in Children FT.CE.12 is a medical device based on a pH-controlled isotonic saline solution formulated with N-acetylcysteine (NAC) and methylsulfonylmethane (MSM). It was developed to support nasal hygiene, hydrate the nasal mucosa, and help manage secretions associated with nasal congestion. In March 2026, Gruppo Farmaimpresa conducted a paediatric clinical&#8230;<\/p>\n","protected":false},"author":3,"featured_media":9501,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","footnotes":""},"categories":[412],"tags":[3136,3131,3135,3134,3137],"class_list":["post-9498","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical-studies","tag-ft-ce-12","tag-isotonic-saline-solution","tag-nasal-congestion-in-children","tag-paediatric-nasal-hygiene","tag-snot-22"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FT.CE.12 Clinical Study on Nasal Congestion in Children<\/title>\n<meta name=\"description\" content=\"The FT.CE.12 clinical study on nasal congestion in children found that the mean SNOT-22 score fell from 8.16 to 3.37 after 16\u201317 days of treatment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pjpharma.it\/en\/ft-ce-12-clinical-study-on-nasal-congestion\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FT.CE.12 Clinical Study on Nasal Congestion in Children\" \/>\n<meta property=\"og:description\" content=\"The FT.CE.12 clinical study on nasal congestion in children found that the mean SNOT-22 score fell from 8.16 to 3.37 after 16\u201317 days of treatment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pjpharma.it\/en\/ft-ce-12-clinical-study-on-nasal-congestion\/\" \/>\n<meta property=\"og:site_name\" content=\"PJ PHARMA\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-16T07:04:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pjpharma.it\/wp-content\/uploads\/2026\/11\/Bambino-raffreddato-con-sciarpa-blu.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1672\" \/>\n\t<meta property=\"og:image:height\" content=\"941\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"giusy\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"giusy\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pjpharma.it\\\/en\\\/ft-ce-12-clinical-study-on-nasal-congestion\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pjpharma.it\\\/en\\\/ft-ce-12-clinical-study-on-nasal-congestion\\\/\"},\"author\":{\"name\":\"giusy\",\"@id\":\"https:\\\/\\\/www.pjpharma.it\\\/en\\\/#\\\/schema\\\/person\\\/68d46a7f1517c6578046391a7778943d\"},\"headline\":\"FT.CE.12: Clinical Study on Nasal Congestion\",\"datePublished\":\"2026-11-16T07:04:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pjpharma.it\\\/en\\\/ft-ce-12-clinical-study-on-nasal-congestion\\\/\"},\"wordCount\":888,\"publisher\":{\"@id\":\"https:\\\/\\\/www.pjpharma.it\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pjpharma.it\\\/en\\\/ft-ce-12-clinical-study-on-nasal-congestion\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pjpharma.it\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/Bambino-raffreddato-con-sciarpa-blu.png\",\"keywords\":[\"FT.CE.12\",\"isotonic saline solution\",\"nasal congestion in children\",\"paediatric nasal hygiene\",\"SNOT-22\"],\"articleSection\":[\"Clinical Studies\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pjpharma.it\\\/en\\\/ft-ce-12-clinical-study-on-nasal-congestion\\\/\",\"url\":\"https:\\\/\\\/www.pjpharma.it\\\/en\\\/ft-ce-12-clinical-study-on-nasal-congestion\\\/\",\"name\":\"FT.CE.12 Clinical Study on Nasal Congestion in Children\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pjpharma.it\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pjpharma.it\\\/en\\\/ft-ce-12-clinical-study-on-nasal-congestion\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pjpharma.it\\\/en\\\/ft-ce-12-clinical-study-on-nasal-congestion\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pjpharma.it\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/Bambino-raffreddato-con-sciarpa-blu.png\",\"datePublished\":\"2026-11-16T07:04:00+00:00\",\"description\":\"The FT.CE.12 clinical study on nasal congestion in children found that the mean SNOT-22 score fell from 8.16 to 3.37 after 16\u201317 days of treatment.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pjpharma.it\\\/en\\\/ft-ce-12-clinical-study-on-nasal-congestion\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pjpharma.it\\\/en\\\/ft-ce-12-clinical-study-on-nasal-congestion\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.pjpharma.it\\\/en\\\/ft-ce-12-clinical-study-on-nasal-congestion\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pjpharma.it\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/Bambino-raffreddato-con-sciarpa-blu.png\",\"contentUrl\":\"https:\\\/\\\/www.pjpharma.it\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/Bambino-raffreddato-con-sciarpa-blu.png\",\"width\":1672,\"height\":941},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pjpharma.it\\\/en\\\/ft-ce-12-clinical-study-on-nasal-congestion\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pjpharma.it\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FT.CE.12: Clinical Study on Nasal Congestion\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pjpharma.it\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.pjpharma.it\\\/en\\\/\",\"name\":\"PJPharma\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.pjpharma.it\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pjpharma.it\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.pjpharma.it\\\/en\\\/#organization\",\"name\":\"PJPharma\",\"url\":\"https:\\\/\\\/www.pjpharma.it\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.pjpharma.it\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.pjpharma.it\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/LOGO_PJ-17.png\",\"contentUrl\":\"https:\\\/\\\/www.pjpharma.it\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/LOGO_PJ-17.png\",\"width\":708,\"height\":700,\"caption\":\"PJPharma\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pjpharma.it\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pjpharma.it\\\/en\\\/#\\\/schema\\\/person\\\/68d46a7f1517c6578046391a7778943d\",\"name\":\"giusy\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e7dc775e86376ea9e71a78c2adaddfe1152888fd4674ed35b3eed755d49da472?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e7dc775e86376ea9e71a78c2adaddfe1152888fd4674ed35b3eed755d49da472?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e7dc775e86376ea9e71a78c2adaddfe1152888fd4674ed35b3eed755d49da472?s=96&d=mm&r=g\",\"caption\":\"giusy\"},\"url\":\"https:\\\/\\\/www.pjpharma.it\\\/en\\\/author\\\/marketing\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FT.CE.12 Clinical Study on Nasal Congestion in Children","description":"The FT.CE.12 clinical study on nasal congestion in children found that the mean SNOT-22 score fell from 8.16 to 3.37 after 16\u201317 days of treatment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pjpharma.it\/en\/ft-ce-12-clinical-study-on-nasal-congestion\/","og_locale":"en_US","og_type":"article","og_title":"FT.CE.12 Clinical Study on Nasal Congestion in Children","og_description":"The FT.CE.12 clinical study on nasal congestion in children found that the mean SNOT-22 score fell from 8.16 to 3.37 after 16\u201317 days of treatment.","og_url":"https:\/\/www.pjpharma.it\/en\/ft-ce-12-clinical-study-on-nasal-congestion\/","og_site_name":"PJ PHARMA","article_published_time":"2026-11-16T07:04:00+00:00","og_image":[{"width":1672,"height":941,"url":"https:\/\/www.pjpharma.it\/wp-content\/uploads\/2026\/11\/Bambino-raffreddato-con-sciarpa-blu.png","type":"image\/png"}],"author":"giusy","twitter_card":"summary_large_image","twitter_misc":{"Written by":"giusy","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pjpharma.it\/en\/ft-ce-12-clinical-study-on-nasal-congestion\/#article","isPartOf":{"@id":"https:\/\/www.pjpharma.it\/en\/ft-ce-12-clinical-study-on-nasal-congestion\/"},"author":{"name":"giusy","@id":"https:\/\/www.pjpharma.it\/en\/#\/schema\/person\/68d46a7f1517c6578046391a7778943d"},"headline":"FT.CE.12: Clinical Study on Nasal Congestion","datePublished":"2026-11-16T07:04:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pjpharma.it\/en\/ft-ce-12-clinical-study-on-nasal-congestion\/"},"wordCount":888,"publisher":{"@id":"https:\/\/www.pjpharma.it\/en\/#organization"},"image":{"@id":"https:\/\/www.pjpharma.it\/en\/ft-ce-12-clinical-study-on-nasal-congestion\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pjpharma.it\/wp-content\/uploads\/2026\/11\/Bambino-raffreddato-con-sciarpa-blu.png","keywords":["FT.CE.12","isotonic saline solution","nasal congestion in children","paediatric nasal hygiene","SNOT-22"],"articleSection":["Clinical Studies"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.pjpharma.it\/en\/ft-ce-12-clinical-study-on-nasal-congestion\/","url":"https:\/\/www.pjpharma.it\/en\/ft-ce-12-clinical-study-on-nasal-congestion\/","name":"FT.CE.12 Clinical Study on Nasal Congestion in Children","isPartOf":{"@id":"https:\/\/www.pjpharma.it\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pjpharma.it\/en\/ft-ce-12-clinical-study-on-nasal-congestion\/#primaryimage"},"image":{"@id":"https:\/\/www.pjpharma.it\/en\/ft-ce-12-clinical-study-on-nasal-congestion\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pjpharma.it\/wp-content\/uploads\/2026\/11\/Bambino-raffreddato-con-sciarpa-blu.png","datePublished":"2026-11-16T07:04:00+00:00","description":"The FT.CE.12 clinical study on nasal congestion in children found that the mean SNOT-22 score fell from 8.16 to 3.37 after 16\u201317 days of treatment.","breadcrumb":{"@id":"https:\/\/www.pjpharma.it\/en\/ft-ce-12-clinical-study-on-nasal-congestion\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pjpharma.it\/en\/ft-ce-12-clinical-study-on-nasal-congestion\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.pjpharma.it\/en\/ft-ce-12-clinical-study-on-nasal-congestion\/#primaryimage","url":"https:\/\/www.pjpharma.it\/wp-content\/uploads\/2026\/11\/Bambino-raffreddato-con-sciarpa-blu.png","contentUrl":"https:\/\/www.pjpharma.it\/wp-content\/uploads\/2026\/11\/Bambino-raffreddato-con-sciarpa-blu.png","width":1672,"height":941},{"@type":"BreadcrumbList","@id":"https:\/\/www.pjpharma.it\/en\/ft-ce-12-clinical-study-on-nasal-congestion\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pjpharma.it\/en\/"},{"@type":"ListItem","position":2,"name":"FT.CE.12: Clinical Study on Nasal Congestion"}]},{"@type":"WebSite","@id":"https:\/\/www.pjpharma.it\/en\/#website","url":"https:\/\/www.pjpharma.it\/en\/","name":"PJPharma","description":"","publisher":{"@id":"https:\/\/www.pjpharma.it\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pjpharma.it\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.pjpharma.it\/en\/#organization","name":"PJPharma","url":"https:\/\/www.pjpharma.it\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.pjpharma.it\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.pjpharma.it\/wp-content\/uploads\/2025\/07\/LOGO_PJ-17.png","contentUrl":"https:\/\/www.pjpharma.it\/wp-content\/uploads\/2025\/07\/LOGO_PJ-17.png","width":708,"height":700,"caption":"PJPharma"},"image":{"@id":"https:\/\/www.pjpharma.it\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.pjpharma.it\/en\/#\/schema\/person\/68d46a7f1517c6578046391a7778943d","name":"giusy","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/e7dc775e86376ea9e71a78c2adaddfe1152888fd4674ed35b3eed755d49da472?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e7dc775e86376ea9e71a78c2adaddfe1152888fd4674ed35b3eed755d49da472?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e7dc775e86376ea9e71a78c2adaddfe1152888fd4674ed35b3eed755d49da472?s=96&d=mm&r=g","caption":"giusy"},"url":"https:\/\/www.pjpharma.it\/en\/author\/marketing\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pjpharma.it\/en\/wp-json\/wp\/v2\/posts\/9498","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pjpharma.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pjpharma.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pjpharma.it\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pjpharma.it\/en\/wp-json\/wp\/v2\/comments?post=9498"}],"version-history":[{"count":2,"href":"https:\/\/www.pjpharma.it\/en\/wp-json\/wp\/v2\/posts\/9498\/revisions"}],"predecessor-version":[{"id":9504,"href":"https:\/\/www.pjpharma.it\/en\/wp-json\/wp\/v2\/posts\/9498\/revisions\/9504"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pjpharma.it\/en\/wp-json\/wp\/v2\/media\/9501"}],"wp:attachment":[{"href":"https:\/\/www.pjpharma.it\/en\/wp-json\/wp\/v2\/media?parent=9498"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pjpharma.it\/en\/wp-json\/wp\/v2\/categories?post=9498"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pjpharma.it\/en\/wp-json\/wp\/v2\/tags?post=9498"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}